Table of Contents
<< Previous Issue | Mar 2024 (Vol: 2024, Issue: 3) |
- Section: Mergers & Acquisitions
-
Gilead to Acquire CymaBay Therapeutics and its Liver Disease Drug for US$4.3 B
- Section: Research & Development
-
Merck KGaA Pays C4 Therapeutics US$16 M Upfront for Protein Degraders